Positive News SentimentPositive NewsNASDAQ:CGEM Cullinan Oncology (CGEM) Stock Forecast, Price & News $10.03 +0.34 (+3.51%) (As of 11:07 AM ET) Add Compare Share Share Today's Range$9.59▼$10.0650-Day Range$9.49▼$11.3552-Week Range$7.78▼$13.98Volume19,104 shsAverage Volume237,630 shsMarket Capitalization$428.68 millionP/E RatioN/ADividend YieldN/APrice Target$26.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cullinan Oncology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside173.5% Upside$26.50 Price TargetShort InterestBearish9.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$8,653 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.14) to ($4.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector637th out of 961 stocksBiological Products, Except Diagnostic Industry104th out of 161 stocks 3.5 Analyst's Opinion Consensus RatingCullinan Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.50, Cullinan Oncology has a forecasted upside of 173.5% from its current price of $9.69.Amount of Analyst CoverageCullinan Oncology has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.80% of the float of Cullinan Oncology has been sold short.Short Interest Ratio / Days to CoverCullinan Oncology has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Cullinan Oncology has recently increased by 33.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCullinan Oncology does not currently pay a dividend.Dividend GrowthCullinan Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEM. Previous Next 3.2 News and Social Media Coverage News SentimentCullinan Oncology has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cullinan Oncology this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CGEM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Cullinan Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cullinan Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,653.00 in company stock.Percentage Held by InsidersOnly 8.82% of the stock of Cullinan Oncology is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cullinan Oncology are expected to decrease in the coming year, from ($4.14) to ($4.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Oncology is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Oncology is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Oncology has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cullinan Oncology (NASDAQ:CGEM) StockCullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More CGEM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEM Stock News HeadlinesSeptember 16, 2023 | americanbankingnews.comShort Interest in Cullinan Oncology, Inc. (NASDAQ:CGEM) Expands By 33.2%September 11, 2023 | msn.comCullinan Oncology: Inexplicably Trading Below Cash Despite Robust DataSeptember 26, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. August 11, 2023 | markets.businessinsider.comBTIG Sticks to Their Buy Rating for Cullinan Management (CGEM)August 10, 2023 | finance.yahoo.comCullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comCullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaAugust 3, 2023 | finance.yahoo.comREZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsJuly 7, 2023 | markets.businessinsider.comAnalyst Ratings for Cullinan OncologySeptember 26, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. July 7, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Cullinan Management (CGEM)June 15, 2023 | msn.comTD Cowen Initiates Coverage of Cullinan Oncology (CGEM) with Outperform RecommendationJune 15, 2023 | markets.businessinsider.comAnalyst Expectations for Cullinan Oncology's FutureJune 15, 2023 | markets.businessinsider.comExpert Ratings for Cullinan OncologyJune 9, 2023 | finance.yahoo.comWhy Shares of Cullinan Oncology Jumped This WeekJune 7, 2023 | markets.businessinsider.comCullinan Management (CGEM) Receives a Buy from SVB SecuritiesJune 5, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Cullinan Management (CGEM)May 30, 2023 | markets.businessinsider.comCullinan Management (CGEM) Gets a Buy from BTIGMay 26, 2023 | msn.comHC Wainwright & Co. Reiterates Cullinan Oncology (CGEM) Buy RecommendationMay 26, 2023 | msn.comCullinan gains as early trial for cancer drug indicates complete remissionMay 25, 2023 | finance.yahoo.comCullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023May 15, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Cullinan Management (CGEM)May 12, 2023 | msn.comHC Wainwright & Co. Maintains Cullinan Oncology (CGEM) Buy RecommendationMay 11, 2023 | finance.yahoo.comCullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial ResultsApril 26, 2023 | finance.yahoo.comCullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023April 20, 2023 | finance.yahoo.comCullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology DaysApril 2, 2023 | benzinga.comCullinan Oncology Inc (CGEM) is down -2.57% in a Week, Should You Accumulate?March 27, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Cullinan OncologySee More Headlines Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEM Company Calendar Last Earnings8/10/2023Today9/26/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CGEM CUSIPN/A CIK1789972 Webwww.cullinanoncology.com Phone617-410-4650FaxN/AEmployees62Year FoundedN/APrice Target and Rating Average Stock Price Forecast$26.50 High Stock Price Forecast$34.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+164.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$111.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.92% Return on Assets-25.60% Debt Debt-to-Equity RatioN/A Current Ratio25.32 Quick Ratio25.32 Sales & Book Value Annual Sales$18.94 million Price / Sales22.63 Cash Flow$2.58 per share Price / Cash Flow3.89 Book Value$11.73 per share Price / Book0.86Miscellaneous Outstanding Shares42,740,000Free Float38,966,000Market Cap$428.68 million OptionableNot Optionable Beta0.15 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Nadim Ahmed (Age 55)Pres, CEO & Director Comp: $1.14MDr. Patrick A. Baeuerle Ph.D. (Age 65)Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board Comp: $763.73kMr. Jeffrey Trigilio (Age 38)CFO & Treasurer Comp: $727.99kDr. Jennifer Michaelson Ph.D. (Age 55)Chief Scientific Officer Ms. Jacquelyn L. Sumer J.D. (Age 44)Chief Legal Officer, Chief Compliance Officer & Corp. Sec. Ms. Rose WeldonSr. VP of CommunicationsMr. Steve AndreChief HR OfficerDr. Corinne Savill Ph.D. (Age 64)Chief Bus. Officer Dr. Jeffrey Jones M.B.A. (Age 51)M.D., M.P.H., Chief Medical Officer Mr. Kevin A. JohnstonChief Technical Operations OfficerMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSCoherus BioSciencesNASDAQ:CHRSIcosavaxNASDAQ:ICVXAgenusNASDAQ:AGENScholar RockNASDAQ:SRRKView All CompetitorsInsiders & InstitutionsCHI Advisors LLCBought 64,729 shares on 8/22/2023Ownership: 7.988%Virginia Retirement Systems ET ALBought 64,800 shares on 8/22/2023Ownership: 0.152%California State Teachers Retirement SystemBought 1,719 shares on 8/21/2023Ownership: 0.055%Nuveen Asset Management LLCBought 5,103 shares on 8/16/2023Ownership: 0.181%Citadel Advisors LLCBought 600 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CGEM Stock - Frequently Asked Questions Should I buy or sell Cullinan Oncology stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGEM shares. View CGEM analyst ratings or view top-rated stocks. What is Cullinan Oncology's stock price forecast for 2023? 4 brokerages have issued 12-month price targets for Cullinan Oncology's stock. Their CGEM share price forecasts range from $19.00 to $34.00. On average, they predict the company's stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 164.2% from the stock's current price. View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts. How have CGEM shares performed in 2023? Cullinan Oncology's stock was trading at $10.55 at the beginning of 2023. Since then, CGEM stock has decreased by 4.9% and is now trading at $10.03. View the best growth stocks for 2023 here. Are investors shorting Cullinan Oncology? Cullinan Oncology saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,650,000 shares, an increase of 33.2% from the August 15th total of 1,990,000 shares. Based on an average daily trading volume, of 258,700 shares, the days-to-cover ratio is currently 10.2 days. Currently, 9.8% of the company's stock are sold short. View Cullinan Oncology's Short Interest. When is Cullinan Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our CGEM earnings forecast. How were Cullinan Oncology's earnings last quarter? Cullinan Oncology, Inc. (NASDAQ:CGEM) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.17. When did Cullinan Oncology IPO? (CGEM) raised $149 million in an initial public offering on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. What is Cullinan Oncology's stock symbol? Cullinan Oncology trades on the NASDAQ under the ticker symbol "CGEM." Who are Cullinan Oncology's major shareholders? Cullinan Oncology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include CHI Advisors LLC (7.99%), Franklin Resources Inc. (5.93%), BlackRock Inc. (5.35%), Braidwell LP (4.47%), American International Group Inc. (3.14%) and Kennedy Capital Management LLC (1.27%). Insiders that own company stock include Ansbert Gadicke, Bioscience I 2017 Ltd F2, Bvf Partners L P/Il, Corrine Savill, Jeffrey Alan Jones, Jeffrey Trigilio, Jennifer Michaelson, Leigh Zawel, Nadim Ahmed, Oncology Impact Fund LP Ubs and Vision Scs F2. View institutional ownership trends. How do I buy shares of Cullinan Oncology? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cullinan Oncology's stock price today? One share of CGEM stock can currently be purchased for approximately $10.03. How much money does Cullinan Oncology make? Cullinan Oncology (NASDAQ:CGEM) has a market capitalization of $428.68 million and generates $18.94 million in revenue each year. The company earns $111.21 million in net income (profit) each year or ($3.37) on an earnings per share basis. How can I contact Cullinan Oncology? The official website for the company is www.cullinanoncology.com. The company can be reached via phone at 617-410-4650 or via email at investors@cullinanoncology.com. This page (NASDAQ:CGEM) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.